newsfilter
← Latest News
PR Newswire·

OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

EWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the